From GlobeNewswire: 2024-05-10 08:00:00

Prime Medicine received FDA clearance for its Prime Editing product, PM359, for CGD treatment. Initial data from Phase 1/2 trial expected in 2025. New preclinical data on Prime Editing technology presented at scientific meetings. Tony Coles, M.D. appointed as senior advisor. Financial results for Q1 2024 reported, with a cash position of $224.2 million as of March 31, 2024. Prime Medicine aims to bring Prime Editing-based products to patients and strengthen its platform across various target tissues. Initial data from PM359 clinical trial expected in 2025. Multi-organ studies showcase potential of Prime Editing technology. Tony Coles joins as senior advisor to support company growth. Financial results for Q1 2024 reveal a net loss of $45.8 million. Cash position as of March 31, 2024 is $224.2 million.



Read more at GlobeNewswire:: Prime Medicine Reports First Quarter 2024 Financial Results